Appointment of Dr Adrian Kilcoyne to Scientific Advisory Board
Poolbeg Pharma, a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the appointment of Dr Adrian Kilcoyne to its Scientific Advisory Board.
Dr Kilcoyne brings over 20 years of clinical expertise with strategic drug development leadership, focusing on innovative therapies that address unmet medical needs in oncology and immunology and, in particular, brings deep knowledge of haematological malignancies, T-cell therapies and Cytokine Release Syndrome ("CRS").
Dr Kilcoyne is currently Chief Medical Officer at Cellectis SA, focusing on the development of allogeneic CAR-T therapies. He was previously Chief Medical Officer and Head of Research & Development at Celularity Inc., where he advanced oncology-focused allogeneic CAR-T and natural killer (NK) cell therapy programmes. He also served as Chief Medical Officer at Humanigen Inc., helping to build the immunology and oncology portfolios, focusing on the cytokine pathway, CAR-T therapies, immunotherapies and Antibody Drug Conjugates in haematology and solid tumours. Across his career, he has held senior leadership roles in research & development, medical affairs, commercial strategy, health economics and outcomes research at major pharmaceutical and biotechnology companies including AstraZeneca, Celgene, Sanofi, Roche and Eli Lilly.
Dr Kilcoyne's clinical training began after graduating from Trinity College Dublin Medical School. He trained in Gynaecological Oncology at Hammersmith Hospital, London and later pursued advanced public health training at Oxford, earning a Master's in Public Health. He subsequently completed professional training in pharmaceutical medicine and earned an MBA from Warwick Business School.
Prof Luke O'Neill, Chair of the Scientific Advisory Board of Poolbeg Pharma, said:
We are delighted to welcome Dr Kilcoyne to Poolbeg's Scientific Advisory Board. He brings a wealth of experience in oncology and cell therapy drug development, combined with deep clinical insight and regulatory expertise which will be invaluable to us as we progress POLB 001 through the TOPICAL trial with the ultimate aim of transforming cancer care for patients and healthcare systems.
Dr Adrian Kilcoyne, Scientific Advisory Board Member of Poolbeg Pharma, said:
I am pleased to join the Scientific Advisory Board of Poolbeg Pharma and to have the opportunity to contribute to the development of POLB 001. Having seen first-hand both the clinical impact on patients and the economic burden on healthcare systems posed by immunotherapy related CRS, I believe POLB 001 has the potential to transform the patient experience. The prevention of CRS remains a significant unmet need and addressing it may enable access for a greater number of patients to life-saving immunotherapies.
